(4R,5S,6S,7R)-4,7-Diisobutyl-5,6-bis-(2-trimethylsilanyl-ethoxymethoxy)-[1,3]diazepan-2-one | 1054652-16-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂卓
• 英文名称: (4R,5S,6S,7R)-4,7-Diisobutyl-5,6-bis-(2-trimethylsilanyl-ethoxymethoxy)-[1,3]diazepan-2-one
• 英文别名: (4R,5S,6S,7R)-4,7-bis(2-methylpropyl)-5,6-bis(2-trimethylsilylethoxymethoxy)-1,3-diazepan-2-one
• CAS: 1054652-16-2
• 化学式: C₂₅H₅₄N₂O₅Si₂
• 分子量: 518.885
• InChiKey: AJFXSSDAAGSBAR-LWSSLDFYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.52
• 重原子数：
  34
• 可旋转键数：
  16
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.96
• 拓扑面积：
  78
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (4R,5S,6S,7R)-4,7-Diisobutyl-5,6-bis-(2-trimethylsilanyl-ethoxymethoxy)-[1,3]diazepan-2-one 在 盐酸 、 sodium hydride 作用下， 以 1,4-二氧六环 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 36.0h， 生成 (4R,5S,6S,7R)-1,3-Dibenzyl-5,6-dihydroxy-4,7-diisobutyl-[1,3]diazepan-2-one
  参考文献：
  名称：

  Preparation and Structure−Activity Relationship of Novel P1/P1‘-Substituted Cyclic Urea-Based Human Immunodeficiency Virus Type-1 Protease Inhibitors

  摘要：

  A series of novel P1/P1'-substituted cyclic urea-based HIV-1 protease inhibitors was prepared. Three different synthetic schemes were used to assemble these compounds. The first approach uses amino acid-based starting materials and was originally used to prepare DMP 323. The other two approaches use L-tartaric acid or L-mannitol as the starting material. The required four contiguous R,S,S,R centers of the cyclic urea scaffold are introduced using substrate control methodology. Each approach has specific advantages based on the desired P1/P1' substituent. Designing analogs based on the enzyme's natural substrates provided compounds with reduced activity. Attempts at exploiting hydrogen bond sites in the S1/S1' pocket, suggested by molecular modeling studies, were not fruitful. Several analogs had better binding affinity compared to our initial leads. Modulating the compound's physical properties led to a 10-fold improvement in translation resulting in better overall antiviral activity.

  DOI：

  10.1021/jm960083n
• 作为产物：
  描述：

  N-苄氧羰基-D-亮胺酸 在 palladium dihydroxide N-甲基吗啉 、 lithium aluminium tetrahydride 、 [VCl3(thf)3] 、 铜 、 N,N-二异丙基乙胺 、 锌 、 环己烯 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 61.25h， 生成 (4R,5S,6S,7R)-4,7-Diisobutyl-5,6-bis-(2-trimethylsilanyl-ethoxymethoxy)-[1,3]diazepan-2-one
  参考文献：
  名称：

  Preparation and Structure−Activity Relationship of Novel P1/P1‘-Substituted Cyclic Urea-Based Human Immunodeficiency Virus Type-1 Protease Inhibitors

  摘要：

  A series of novel P1/P1'-substituted cyclic urea-based HIV-1 protease inhibitors was prepared. Three different synthetic schemes were used to assemble these compounds. The first approach uses amino acid-based starting materials and was originally used to prepare DMP 323. The other two approaches use L-tartaric acid or L-mannitol as the starting material. The required four contiguous R,S,S,R centers of the cyclic urea scaffold are introduced using substrate control methodology. Each approach has specific advantages based on the desired P1/P1' substituent. Designing analogs based on the enzyme's natural substrates provided compounds with reduced activity. Attempts at exploiting hydrogen bond sites in the S1/S1' pocket, suggested by molecular modeling studies, were not fruitful. Several analogs had better binding affinity compared to our initial leads. Modulating the compound's physical properties led to a 10-fold improvement in translation resulting in better overall antiviral activity.

  DOI：

  10.1021/jm960083n

文献信息

• The synthesis of symmetrical and unsymmetrical P1/P1′ cyclic ureas as HIV protease inhibitors
  作者：Mona Patel、Robert F. Kaltenbach、David A. Nugiel、Robert J. McHugh、Prabhakar K. Jadhav、Lee T. Bacheler、Beverly C. Cordova、Ronald M. Klabe、Susan Erickson-Viitanen、Sena Garber、Carol Reid、Steven P. Seitz

  DOI：10.1016/s0960-894x(98)00175-9

  日期：1998.5

  Cyclic urea SD146, a potent HIV protease inhibitor bearing a flat resistance profile, possessed poor solubility and bioavailability, which precluded further development of the compound. In an effort to improve upon the pharmacokinetic profile of the compound, several analogs modified at the P1/P1' residues were prepared and evaluated. Several of those compounds displayed significant improvement of

  环状脲SD146是一种有效的HIV蛋白酶抑制剂，具有平坦的抗药性，但溶解性和生物利用度较差，因此无法进一步开发该化合物。为了改善该化合物的药代动力学特性，制备并评估了在P1 / P1'残基上修饰的几种类似物。这些化合物中的几种显示出物理性能的显着改善。